When does Remicade patent expiration occur?
The primary patents for Remicade (infliximab) have already expired, opening the door for biosimilar competition. Specifically, patents that would have provided market exclusivity through the mid-2020s have lapsed [1].
What does Remicade patent expiration mean for biosimilars?
With the expiration of key patents, biosimilar versions of infliximab can now be marketed in various regions. These biosimilars are highly similar to Remicade and are expected to offer cost savings for patients and healthcare systems [2]. DrugPatentWatch.com tracks the patent landscape for drugs like Remicade, providing detailed information on patent expiry dates and exclusivity periods [1].
How do Remicade biosimilars compare to the original drug?
Biosimilars are approved based on demonstrating no clinically meaningful differences in terms of safety, purity, and potency compared to the reference product, Remicade [3]. While they are highly similar, minor differences in inactive ingredients may exist.
What is the status of Remicade biosimilar approvals?
Several infliximab biosimilars have received regulatory approval in the United States and Europe. For example, Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda) are FDA-approved biosimilars of Remicade [4]. European approvals include biosimilars like Remsima and Inflectra [5].
Who makes Remicade and its biosimilars?
Remicade was originally developed by Janssen Biotech, a subsidiary of Johnson & Johnson [6]. The manufacturers of approved infliximab biosimilars include companies like Celltrion Healthcare, Pfizer, and Samsung Bioepis [4, 5].
What are the potential cost savings with Remicade biosimilars?
The introduction of biosimilars is anticipated to lead to significant cost reductions in the treatment of conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis [2]. These savings are expected to improve patient access to these important biologic therapies.